|
Bedford Laboratories receives FDA approval for Methylprednisolone Sodium Succinate for Injection, USP |
|
|
|
23 Feb 2007 |
Announced FDA approval to begin shipping Methylprednisolone Sodium Succinate for Injection, USP.
BEDFORD, OH, USA | Feb 22, 2007 | Bedford Laboratories™, a division of Ben Venue Laboratories Inc, announced FDA approval to begin shipping Methylprednisolone Sodium Succinate for Injection, USP. This product is AP rated and is equivalent to Solu-Medrol® by Pfizer. Methylprednisolone is an adrenocorticosteroid hormone with multiple indications including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, gastrointestinal diseases, allergic states, ophthalmic diseases and neoplastic diseases.
"As part of our continuing strategy to expand our product portfolio, Bedford Laboratories is pleased to be offering such a widely demanded, and important product," said David Gaugh, Vice President of Bedford Laboratories.
Bedford Laboratories will supply Methylprednisolone Sodium Succinate for Injection, USP as a sterile lyophilized powder in four single dose presentations: 40 mg, 125 mg, 500 mg and 1 gram.
SOURCE: Bedford Laboratories |
